Dormant
PRPO · Precipio, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close, though 1 is sitting on its line.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on the last session; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Precipio’s diagnostics growth and renewed operating cash generation support a conditional recovery toward its recorded $32.37 high. A weekly close above that level confirms the price case; a weekly close below the 2026-09-11 reference close of $27.32 invalidates it.
Kill line
A weekly close below $27.32 invalidates the recovery thesis by losing the 2026-09-11 adjusted reference close; this level is a research boundary, not an established support shelf.
Pick status
Open commitment scored if the kill line above fires How this is scored →Latest analysis and events for PRPO —
As of 13 September 2026, the latest FrontierPicks analysis for Precipio, Inc. (PRPO): Precipio’s diagnostics growth and renewed operating cash generation support a conditional recovery toward its recorded $32.37 high. A weekly close above that level confirms the price case; a weekly close below the 2026-09-11 reference close of $27.32 invalidates it.
Kill line: A weekly close below $27.32 invalidates the recovery thesis by losing the 2026-09-11 adjusted reference close; this level is a research boundary, not an established support shelf.
Current Thesis
Precipio’s diagnostics growth and return to operating cash generation support a conditional recovery thesis: a weekly close above the recorded $32.37 high would confirm it, while a weekly close below $27.32 would invalidate it. Both market references come from the adjusted price series dated 2026-09-11.
The interpretation is that the narrative is maturing — management announced performance-option vesting on 2026-05-13, and the latest company release remains the 2026-08-14 earnings report. The September price snapshot shows positive three-month performance alongside weaker recent momentum; this does not establish expanding participation. Company release archive
Bullish and bearish views on Precipio, Inc.
The model's bull view on Precipio, Inc. (PRPO), in brief: Revenue expanded across both businesses. The bear view: Revenue growth did not preserve earnings. Both cases follow in full.
Bull Case
- Revenue expanded across both businesses. In its 2026-08-14 release, Precipio reported second-quarter pathology revenue of $6.1 million versus $6.0 million in the first quarter, and product revenue of $0.9 million versus $0.66 million. Company results
- Operations generated cash again. The same release reported $0.7 million of second-quarter operating cash inflow and $0.4 million of adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), versus negative $0.2 million of adjusted EBITDA in the first quarter. A single quarterly recovery cannot establish durable cash generation. Company results
Bear Case
- Revenue growth did not preserve earnings. Benzinga’s 2026-08-14 report recorded sales of $7.021 million versus $5.654 million a year earlier, but a loss per share of $0.12 versus earnings of $0.05. The company’s reconciliation separately reported a second-quarter net loss of $0.2 million. Company reconciliation
- Vested awards require careful interpretation. On 2026-05-13, Precipio announced that management’s 2025 performance options had vested following the required price appreciation. Vesting is an observable compensation event; that announcement does not establish exercise, insider selling or subsequent market supply. Company options announcement
Setup & Price Structure
The 2026-09-11 adjusted close was $27.32, with the shares up 23.6% over three months and 15.6% below the recorded 52-week high of $32.37. The 14-period relative strength index (RSI) was 35.3. These measurements describe a retreat within a positive three-month price change; they do not establish a completed base.
The $27.32 reference close is the explicit boundary for this recovery hypothesis, not a verified historical support shelf. The supplied observations contain no moving-average level, volume history, short-interest measurement or retail-participation series. Crowding cannot be established from this evidence.
The low-conviction forecast concerns a weekly close above $32.37 before a weekly close below $27.32. The reference-close boundary and the September momentum reading limit the case despite the August operating improvement.
Catalyst Calendar (next 30 days)
- 2026-09-13 through 2026-10-13: No company-confirmed catalyst was identified for this window. The company’s update-call archive lists 2026-08-17 as its latest quarterly call; that event has elapsed. Shareholder updates
- ~2026-11-16, estimated: MarketBeat estimates the next quarterly earnings release for this date; company confirmation is absent. That report would test whether the August cash-generation recovery persisted. MarketBeat earnings calendar
What Would Change Our Mind
Failure to retain the September reference close would end the published recovery case: a weekly close below $27.32 is the observable invalidation. This is a price-thesis boundary, not proof that the underlying business has deteriorated.
A return to negative quarterly operating cash flow would separately contradict the durability interpretation attached to the 2026-08-14 results. Conversely, another positive quarter would extend the evidence but would not by itself establish a lasting trend.
Correlation Notes
FrontierPicks’ Medtech & diagnostics assessment moved from accelerating on 2026-08-30 to maturing on 2026-09-06 and saturated on 2026-09-13. That is a dated group assessment, not a measured correlation or a finding that Precipio itself is saturated.
The listed peers include INSP, ATRC, BFLY and TXG, but no paired return series accompanies the 2026-09-13 assessment. The sample is insufficient to claim that their price movements explain PRPO’s September structure. The single-name thesis therefore rests on its reported operations and explicit market-close conditions.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera launch and Parse patent verdict support a recovery thesis tested by a weekly close above $65.12 before a weekly close below $58.57. The September 10, 2026 daily close of $66.38 leaves weekly confirmation, shipment execution and the requested injunction unresolved.
HAE
Haemonetics Corporation
The CSL option is now priced by the sell side and still unpriced by the company: six analyst actions since 2026-08-07 took the top of the range to Raymond James' $125 on 2026-09-03, yet the 2026-09-04 close of $102.92 sits 5.4% under the 2026-08-18 high of $108.80, leaving a maturing narrative holding a gap it cannot re-rate without a number until the ~2026-11-05 Q2 print.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
See also · stocks to watch